IP Library Granted Patent US 10,323,288
Granted Patent B2
US 10,323,288 · App. 15/267,615 · Granted Jun 18, 2019

Compositions, methods and kits to detect adenovirus nucleic acids

Inventors: Emily Ziegler (Milwaukee, WI); Jessica Townsend (Milwaukee, WI)
Assignee: GEN-PROBE INCORPORATED
C12Q1/701C07H21/02C07H21/04C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,323,288
App. No.
15/267,615
Granted
Jun 18, 2019
Kind
B2
Abstract

The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Adenovirus nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers.

Claims (15)

1. A composition for use in an Adenovirus target nucleic acid amplification and detection assay comprising (i) at least two amplification oligomers capable of stably hybridizing to Adenovirus target nucleic acid and (ii) at least one detectably labeled detection probe oligomer capable of stably hybridizing to an amplicon generated by said at least two amplification oligomers,

wherein each of said at least two amplification oligomers is from 10 to 50 nucleotides in length and wherein the amplification oligomers are respectively configured to specifically hybridize to regions within a target sequence of Adenovirus selected from the group consisting of from nucleotides 1 to 99 and from nucleotides 83 to 175 of Accession Number AB330090.1 (SEQ ID No. 47) wherein,

at least one of said at least two amplification oligomers is complementary to the targeted Adenovirus nucleic acid within nucleotides 1 to 99 of SEQ ID No. 47 and comprises a target hybridizing sequence as set forth in SEQ ID No: 25 with no mismatches or with 1 or 2 mismatches to the targeted Adenovirus nucleic acid; and

at least one of said at least two amplification oligomers is complementary to the targeted Adenovirus nucleic acid within nucleotides 83 to 175 of SEQ ID No. 47 and comprises a target hybridizing sequence as set forth in SEQ ID No: 27 with no mismatches or with 1 or 2 mismatches to the targeted Adenovirus nucleic acid; and

wherein one of said at least one detection probe oligomer is from 20 to 22 contiguous nucleotides in length and comprises a target hybridizing sequence contained within SEQ ID No. 1 or the complement thereof, with no mismatches or with 1 or 2 mismatches to SEQ ID No. 1.

2. The composition according to claim 1 , wherein at least one first amplification oligomer comprises a target hybridizing sequence as set forth in SEQ ID No. 25 and/or SEQ ID No. 26 and wherein at least one second amplification oligomer comprises a target hybridizing sequence as set forth in SEQ ID No. 27 and/or SEQ ID No. 28.

3. The composition according to claim 2 , wherein the first and second amplification oligomers are selected from the group consisting of SEQ ID Nos 25, 26, 27 and 28; SEQ ID Nos 26, 27 and 28; SEQ ID Nos 25, 26 and 28; SEQ ID Nos 25, 26 and 27; SEQ ID Nos 25, 27 and 28; SEQ ID Nos 25 and 27; SEQ ID Nos 25 and 28; SEQ ID Nos 26 and 27 and SEQ ID Nos 26 and 28 or a combination of two or more thereof.

4. The composition according to claim 1 , wherein the detection probe comprises a sequence selected from the group consisting of SEQ ID Nos 17, 19, 21, 23, 24, 29, 36 and 37 or a combination of two or more thereof; preferably wherein the detection probe comprises a sequence as set forth in SEQ ID No. 36 and/or SEQ ID No. 37.

5. The composition according to claim 2 , wherein the detection probe comprises a sequence selected from the group consisting of SEQ ID Nos 17, 19, 21, 23, 24, 29, 36 and 37 or a combination of two or more thereof; preferably wherein the detection probe comprises a sequence as set forth in SEQ ID No. 36 and/or SEQ ID No. 37.

6. The composition according to claim 3 , wherein the detection probe comprises a sequence selected from the group consisting of SEQ ID Nos 17, 19, 21, 23, 24, 29, 36 and 37 or a combination of two or more thereof; preferably wherein the detection probe comprises a sequence as set forth in SEQ ID No. 36 and/or SEQ ID No. 37.

7. A kit comprising the composition claim 1 and optionally a set of instructions for performing same.

8. The kit of claim 7 , wherein at least one of the at least two amplification oligomers is in a first container and the at least one detectably labeled detection probe oligomer is in a second container.

9. The kit of claim 7 , wherein at least one of the at least two amplification oligomers and at least one detectably labeled detection probe are in a single container.

10. The kit of claim 7 , wherein the at least one detectably labeled detection probe oligomer is labeled with a fluorescent/quencher (F/Q) pair.

11. The composition of claim 1 , wherein the at least one detectably labeled detection probe oligomer is labeled with a fluorescent/quencher (F/Q) pair.

Assignments (8)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 041050/0285 Recorded Apr 23, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED
Reel/Frame 075455/0001 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 040208/0109 Recorded Apr 23, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED
Reel/Frame 075471/0100 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 043524 FRAME: 0162. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 4, 2017
From: ZIEGLER, EMILY L.; TOWNSEND, JESSICA
To: GEN-PROBE PRODESSE, INC.
Reel/Frame 044679/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2017
From: ZIEGLER, EMILY L.; TOWNSEND, JESSICA A.
To: GEN-PROBE INCORPORATED
Reel/Frame 043524/0162 →
SECURITY INTEREST Recorded Jan 23, 2017
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 041050/0285 →
SECURITY AGREEMENT Recorded Oct 3, 2016
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 040208/0109 →
Continuity (4)
Continuation 15012096 · Feb 1, 2016
Continuation 14220466 · Mar 20, 2014
Continuation 13253819 · Oct 5, 2011
Related Publication 20170002431A1 · Jan 5, 2017